Price Alert

Acumen Pharmaceuticals In... (ABOS)

NASDAQ: ABOS · Real-Time Price · USD

1.38

-0.01 (-0.72%)

At close: Sep 04, 2025, 3:59 PM

1.38

0.00%

After-hours: Sep 04, 2025, 04:10 PM EDT

-0.72% (1D)

Bid	1.3
Market Cap	83.59M
Revenue (ttm)	178K
Net Income (ttm)	-136.66M
EPS (ttm)	-2.27
PE Ratio (ttm)	-0.61
Forward PE	-0.85
Analyst	Buy

Ask	1.42
Volume	95,054
Avg. Volume (20D)	459,762
Open	1.40
Previous Close	1.39
Day's Range	1.33 - 1.40
52-Week Range	0.85 - 3.36
Beta	0.14

About ABOS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ABOS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ABOS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-11.27%

Acumen Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription

News

3 days ago · seekingalpha.com

Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Busi...

3 weeks ago · seekingalpha.com

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Di...

1 month ago · businesswire.com

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announ...